By Fineline Cube 
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its bispecific fusion protein JMT106. The study will assess the drug’s efficacy and safety in patients with advanced solid tumors.
JMT106 Mechanism and Targets
JMT106 targets the interferon receptor and GPC3, with the latter being highly expressed in solid tumors such as hepatocellular carcinoma, lung squamous cell carcinoma, and ovarian cancer. This dual-targeting approach is designed to enhance the drug’s anti-tumor effects.
Clinical Trial Prospects
The drug has demonstrated significant anti-tumor effects and good safety in multiple malignant tumor models. The upcoming clinical study aims to further evaluate JMT106’s potential as a novel treatment option for patients with advanced solid tumors, addressing significant unmet medical needs in oncology.-Fineline Info & Tech